Compare Dolby Laboratories, Inc. (DLB) vs Summit Therapeutics Inc (SMMT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Dolby Laboratories, Inc. vs Summit Therapeutics Inc — how do they compare? Dolby Laboratories, Inc. trades at $61.2 (market cap $5.75B), while Summit Therapeutics Inc trades at $15.1 (market cap $12.06B). The key difference: Summit Therapeutics Inc is far larger — about 2.1× Dolby Laboratories, Inc.'s market cap, and Dolby Laboratories, Inc. pays a 2.35% dividend while Summit Therapeutics Inc pays none. Which is the better fit depends on your goals.
| DLB | SMMT | |
|---|---|---|
Market Cap | $5.75B | $12.06B |
Sector | Industrials | Health |
52-Week High | $75.62 | $26.98 |
52-Week Low | $48.51 | $12.55 |
Enterprise Value | $5.12B | $11.39B |
Dividend Yield | 2.35% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DLB trades at $61.39, down 1.14% today, with a bullish technical signal from moving averages and a consensus analyst price target of $87.50. The company has beaten EPS estimates for the last four quarters, including Q2 2026, and maintains strong profitability with an 87.61% gross margin. Recent news highlights growth in Dolby Atmos and auto licensing, though revenue declined year-over-year in Q3 2026.
The outlook is positive with analyst support and operational strength, but risks include licensing volatility and near-term execution challenges. The stock offers upside to the price target, supported by cash flow growth and market expansion in audio-visual technologies.
Summit Therapeutics (SMMT) trades at $15.10, up 1.55% with a bullish technical signal and strong analyst support. The company shows negative profitability metrics with ROE at -192.5% and net income of -$1.08B for 2025, but maintains positive cash flow through financing activities. Recent developments include FDA review of ivonescimab with a November 2026 decision date and expansion into bladder cancer trials, driving investor optimism despite ongoing losses.
The investment case hinges on ivonescimab's regulatory approval potential, with a consensus price target of $27.90 representing 85% upside. Key risks include cash burn concerns, fiduciary duty investigations, and clinical trial outcomes. While fundamentals remain weak, the stock offers high-risk, high-reward potential for speculative biotech investors betting on successful drug commercialization.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Dolby Laboratories, Inc.
Dolby Laboratories Inc develops audio and surround sound for cinema, broadcast, home audio systems, in-car entertainment systems, DVD players, games, televisions, and personal computers. The company generates three fourths of its revenue from licensing its technology to consumer electronics manufacturers around the world. The rest of revenue comes from equipment sales to professional producers and audio engineering services.
Read more on DLB →About Summit Therapeutics Inc
Summit Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of new medicines for the treatment of infectious diseases and other unmet medical needs. The company's lead product candidate is an antibiotic for the treatment of Clostridioides difficile infection (CDI), a serious infection of the colon. Summit Therapeutics is committed to bringing innovative therapies to market to address global health challenges and improve patient outcomes.
Read more on SMMT →
